ATC Code C10AX09
Formula C24H21F2NO3
Molar Mass (g·mol−1) 409,4252
Physical State solid
Melting Point (°C) 163
PKS Value 9,48
CAS Number 163222-33-1
PUB Number DB00973
Drugbank ID DB00973
Solubility practically insoluble in water


Ezetimibe belongs to the group of cholesterol absorption inhibitors and is a lipid-lowering agent used to lower blood cholesterol levels. It is mainly used as an add-on therapy for the treatment of primary hyperlipidemia and in familial hypercholesterolemia.

The discovery and research of ezetimibe began in the early 1990s after intravenous administration of ezetimibe to rats showed that the drug accumulates in the enterocytes of the intestinal villi. This finding prompted studies to investigate the effect of ezetimibe on intestinal cholesterol absorption.



The cholesterol-lowering effect in the blood is mainly prompted by ezetimibe selectively inhibiting the absorption of cholesterol and phytosterol by the small intestine, but without interfering with the absorption of fat-soluble vitamins and nutrients. Inhibition of transport of lipids into the blood is achieved through inhibited binding to the transport protein NPC1L1. As a result, the amount of circulating cholesterol in the blood is reduced.
Ezetimib senkt neben dem Gesamtcholesterin auch das LDL-Cholesterin, das Apo-B-Protein und Triglyzeride und kann eine Erhöhung des HDL-Cholesterins bewirken.


Ezetimibe is rapidly absorbed after oral administration and metabolized to its major active metabolite, ezetimibe glucoronide, and subsequently excreted via bile. The highest concentration of ezetimibe in blood plasma is reached after 4-12 hours, that of ezetimibe glucoronide after 1-2 hours, and circulates with approximately 99% (ezetimibe) and approximately 90% (ezetimibe glucoronide) bound to proteins. Elimination occurs in the feces and to a lesser extent in the urine.


Interactions may occur with antacids, colestyramine, fibrates, and warfarin, among others.


Side effects

Adverse effects such as abdominal pain, diarrhea, flatulence, or fatigue may occur during treatment with ezetimibe.

Toxicological Data

LD50 (oral and intraperitoneal, rat): > 2000 mg/kg

Markus Falkenstätter

Markus Falkenstätter

Markus Falkenstätter ist Autor zu pharmazeutischen Themen in der Medizin-Redaktion von Medikamio. Er befindet sich im letzten Semester seines Pharmaziestudiums an der Universität Wien und liebt das wissenschaftliche Arbeiten im Bereich der Naturwissenschaften.

Mag. pharm Stefanie Lehenauer

Mag. pharm Stefanie Lehenauer

Stefanie Lehenauer ist seit 2020 freie Autorin bei Medikamio und studierte Pharmazie an der Universität Wien. Sie arbeitet als Apothekerin in Wien und ihre Leidenschaft sind pflanzliche Arzneimittel und deren Wirkung.

Your personal medicine assistent

afgis-Qualitätslogo mit Ablauf Jahr/Monat: Mit einem Klick auf das Logo öffnet sich ein neues Bildschirmfenster mit Informationen über Medikamio GmbH & Co KG und sein/ihr Internet-Angebot: medikamio.com/ This website is certified by Health On the Net Foundation. Click to verify.

Search our database for drugs, sorted from A-Z with their effects and ingredients.


All substances with their common uses, chemical components and medical products which contain them.


Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.